drugset
drugset / Trial / NCT07199452

A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

NCT07199452 ↗

Phase 1 Completed 18 enrolled Merck Sharp & Dohme LLC
Non-randomizedCrossoverOpen-labelBasic science

Summary

Researchers have designed a new study medicine called MK-4646 as a new way to treat human immunodeficiency virus (HIV). Rifabutin is a medication used to treat tuberculosis (TB). Researchers want to learn about MK-4646 when taken at the same time as Rifabutin. They want to: Measure a person's blood to find out if the amount of MK-4646 in the blood is the same when MK-4646 is taken alone or with Rifabutin Learn about the safety of MK-4646 when taken alone or with Rifabutin and if people tolerate it

Timeline

Start
2025-10-28
Primary completion
2025-12-27
Completion
2026-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-4646 Unknown — Oral
Subject Rifabutin Small molecule — Oral

Indications

No indication recorded.